EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples

YuTing Liu, Minhua Yang, Kyle Fraser, Danielle Graham, Paul H Weinreb, Andreas Weihofen, Warren D Hirst, Jesse M Cedarbaum, Blake Pepinsky

The Journal of Pharmacology and Experimental Therapeutics · 2025-01 · 392 (1) · 100003

DOI: 10.1124/jpet.124.002199 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025-01. Verfasst von YuTing Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biogen, Cambridge, Massachusetts. Electronic address: christine.liu369@gmail.com. Hauptthemen laut MEDLINE: alpha-Synuclein. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Through its pathological and genetic association with Parkinson disease (PD), α-synuclein (α-syn) remains a favorable therapeutic target that is being investigated using various modalities, including many passive immunotherapy approaches clinically targeting different forms of α-syn and epitopes. Although published studies from some immunotherapy trials have demonstrated engagement in plasma, none has shown direct drug-antigen interactions in the disease-relevant compartment, the central nervous system. Cinpanemab (BIIB054) selectively targets pathological aggregated α-syn with low-affinity binding to monomeric forms. The avidity-driven binding, low drug concentration, and the very low α-syn levels, plus its heterogeneous nature in cerebrospinal fluid (CSF), made it impossible to measure drug-target interactions by conventional assays. Here we overcame these challenges by using zero-length crosslinking to stabilize the BIIB054-α-syn complexes and then quantified the crosslinked complexes using a Meso Scale Discovery electrochemiluminescence assay. CSF samples from healthy volunteers (HVs, n = 46) and individuals with PD (PD, n = 18) from study 228HV101 (phase 1 clinical trial of BIIB054) demonstrated dose- and time-dependent binding of cinpanemab to α-syn with measurable complexes detected at doses ≥15 mg/kg. Complex formation displayed a direct positive correlation to drug concentration (Spearman rank correlation = 0.8295 [HV], 0.8032 [PD] P < .0001 [HV, PD]). The observed binding of cinpanemab to α-syn in CSF is consistent with its low intrinsic affinity for α-syn monomer and provides evidence that the drug is behaving with expected binding dynamics in the central nervous system compartment. SIGNIFICANCE STATEMENT: A zero-length crosslinking method with Meso Scale Discovery detection was developed to enable quantification of cinpanemab-α-synuclein (α-syn) complexes in clinical cerebrospinal fluid samples by preventing signal loss caused by their rapid dissociation. Observed dose- and time-dependent binding was consistent with cinpanemab's affinity for α-syn and provided confidence the drug had engaged its target at the desired site of action. This is the first demonstration of α-syn binding by an antibody in clinical samples from the central nervous system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinHumansProtein BindingMaleDose-Response Relationship, DrugFemaleParkinson DiseaseMiddle AgedAdult

Stichwörter der Autor:innen

Cerebrospinal fluidCinpanemabParkinson’s diseasePharmacodynamicsZero-length crosslinkingα-Synuclein

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • Biogen, Cambridge, Massachusetts. Electronic address: christine.liu369@gmail.com.
  • Biogen, Cambridge, Massachusetts.

Förderung

  • Biogen

Zitieren

APA

Liu, Y., Yang, M., Fraser, K., Graham, D., Weinreb, P. H., Weihofen, A., Hirst, W. D., Cedarbaum, J. M., & Pepinsky, B. (2025). Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. The Journal of Pharmacology and Experimental Therapeutics, 392(1), 100003. https://doi.org/10.1124/jpet.124.002199

Vancouver

Liu Y, Yang M, Fraser K, Graham D, Weinreb PH, Weihofen A, et al. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. The Journal of Pharmacology and Experimental Therapeutics. 2025;392(1):100003. doi:10.1124/jpet.124.002199

BibTeX
@article{Liu2025,
  author = {Liu, YuTing and Yang, Minhua and Fraser, Kyle and Graham, Danielle and Weinreb, Paul H and Weihofen, Andreas and Hirst, Warren D and Cedarbaum, Jesse M and Pepinsky, Blake},
  title = {Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2025},
  volume = {392},
  number = {1},
  pages = {100003},
  doi = {10.1124/jpet.124.002199}
}
Kostenlos starten →